The term derives from the Latin sub (under) and cutis (skin). In anatomical usage, the subcutaneous layer , formally called the hypodermis or tela subcutanea , sits below the dermis and above the underlying muscle fascia. It serves primarily as an insulating and energy-storage compartment, and houses blood vessels, lymphatics, and cutaneous nerve branches that supply the skin above.
In pharmacology and clinical practice, "subcutaneous" describes a route of administration in which a substance is introduced into the hypodermis, typically via a short-gauge needle angled at roughly 45–90 degrees to the skin surface. Because the subcutaneous layer has a lower density of blood vessels than muscle tissue, absorption via this route tends to be slower and more sustained than intramuscular administration. This makes the subcutaneous route relevant to the delivery of a range of substances where gradual systemic uptake is desirable.
Under the Australian regulatory framework, the route of administration , including whether a substance is given subcutaneously; forms part of the product information assessed by the Therapeutic Goods Administration (TGA) during registration on the Australian Register of Therapeutic Goods (ARTG). The approved route of administration is a legally binding element of a product's registration; administering a registered therapeutic good by any route not specified in its approval may constitute use outside the approved indication and carries regulatory and safety implications.
In the context of peptides and other compounds sometimes discussed in health and performance settings, it is worth noting that the subcutaneous route is frequently cited in both approved and unapproved contexts. Many peptide products marketed in Australia are not registered on the ARTG; the TGA has stated explicitly that supplying unregistered therapeutic goods, regardless of how they are administered, is illegal under the Therapeutic Goods Act 1989.
Sources: